Mahamaya Lifesciences, a BSE SME-listed agrochemical player that debuted barely a month ago, surged into the spotlight after ace investor Vijay Kedia picked up a meaningful position through a block deal—triggering a sharp, liquidity-driven rally in the counter.
Kedia Securities – Mahamaya Lifesciences Deal Structure
Exchange data reports that Kedia Securities bought 8,91,600 shares of Mahamaya Lifesciences at INR 140 per share on 16 December 2025, translating into a consideration of roughly INR 12.48 crore. The buying price represented about a 2.8% discount to the previous close (INR 144.05), a typical feature in negotiated block transactions.
On the sell side, Almondz Global Securities offloaded 1,51,200 shares at INR 143.64 in the same session, reflecting active churn among institutional/market-facing accounts as the stock’s investor base reshapes post listing.
Vijay Kedia’s entry in Mahamaya Lifesciences pegged his stake at roughly a 3.81% stake, an eye-catching entry size for a recently listed SME name.
Market Response
The immediate market response was decisive. On 17 December 2025, Mahamaya Lifesciences rallied as much as 13% intraday, touching INR 181, which reports called a fresh 52-week / all-time high given the company’s recent debut.
This is a classic SME pattern: when a high-recognition investor takes a visible stake, the signal value can amplify near-term demand—especially in counters with thin floats and lower liquidity, where incremental buying pressure can move prices quickly.
Mahamaya Lifesciences IPO Backdrop
Mahamaya Lifesciences operates in pesticide formulations and crop protection products, with a product set spanning key agrochemical formulations and a growing export footprint across markets such as Egypt, Ethiopia, Jordan, the UAE and Turkey.
The company was listed on 18 November 2025. It had a subdued debut at INR 116 versus an issue price of INR 114, but has since re-rated sharply. Mahamaya Lifesciences share price surged 52.5% from its IPO price.
The INR 70.44 crore IPO comprised a fresh issue of INR 64.28 crore and OFS of INR 6.16 crore. Subscription was 1.63x overall, led by NIIs, with retail participation constrained in part by the relatively high minimum application size.
Fundamental Investors Watching
The “Kedia entry + price pop” narrative is being supported by strong recent reported growth:
- FY25 revenue: INR 267.17 crore (up 64%)
- FY25 PAT: INR 12.94 crore (up 148%)
- FY25 EBITDA: INR 24.64 crore
- Net worth: nearly doubled to INR 49.42 crore
Mahamaya Lifesciences IPO proceeds are slated for equipment purchases, a new technical manufacturing plant, warehouse construction, working capital and general corporate purposes—use of funds that can accelerate growth, but also raises execution expectations.
Final Words
Vijay Kedia’s entry in Mahamaya Lifesciences has put the company firmly on the market’s radar. Whether the stock sustains its re-rating from here will depend less on the one-day spike and more on how consistently the company converts its FY25 momentum into repeatable growth with controlled leverage and clean cash conversion.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.